SKSun H. Kim

Sun H. Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sun H. Kim has a total of 318 co-authors. Here are the top co-authors by number of shared publications:

  • Gerald M. Reaven

    Division of Cardiovascular Medicine (F. Abbasi, C.L., C.S.H., V.H., P.T., F. Abbas, G.M.R., J.W.K.), Stanford University, CA

    23 shared publications
  • Fahim Abbasi

    Stanford Diabetes Research Center Stanford University School of Medicine Stanford California USA

    17 shared publications
  • Cindy Lamendola

    Division of Cardiovascular Medicine (F. Abbasi, C.L., C.S.H., V.H., P.T., F. Abbas, G.M.R., J.W.K.), Stanford University, CA

    13 shared publications
  • Gerald Reaven

    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA

    8 shared publications
  • Kaylene Grove

    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

    8 shared publications
  • Vanessa Tomasso

    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

    8 shared publications

Latest Publications

  • Open Access

    A narrative review of what cohorts have taught us and how they have laid the foundation for much of our understanding of type 2 diabetes

    by Sun H. Kim, Ipsa Arora, Charles Agyemang, Ranjit M. Anjana, Bjørn Olav Åsvold, Marieke Blom, Shilpa N. Bhupathiraju, Amélie Bonnefond, Juliana C. N. Chan, Timothy M. E. Davis, et al.

  • Comment on Wagner et al. Beyond Glucose—Rethinking Prediabetes for Precision Prevention

    by Sun H. Kim, Erin S. Leblanc, Richard Pratley, Anastassios G. Pittas


  • Smartphone-based App to Assess Diabetic Peripheral Neuropathy

    by Rachel A. G. Adenekan, Adeyinka E. Adenekan, Kenneth K. Leung, Srikanth Muppidi, Sarada Sakamuri, Marilyn Tan, Sandra A. Tsai, Modupe Osikomaiya, Allison M. Okamura, Cara M. Nunez, et al.

    Background: Diabetic peripheral neuropathy (DPN) affects approximately 50% of individuals with diabetes and is a risk factor for amputations. Unfortunately, foot exams and screening tools are inconsistent and miss early-stage nerve damage. A smartphone-based application that delivers controlled vibrations, records patient responses, and computes a vibration perception threshold (SVPT) may present an accessible, precise monitoring avenue. This study assesses the clinical relevance and precision of SVPTs for measuring large-fiber sensory deficits in patients with diabetes. Methods: We measured SVPTs in 71 patients with pre-diabetes or diabetes and compared their efficacy with tuning fork exams. We analyzed the correlation between SVPT and Rydel-Seiffer tuning fork (RSTF) scores, along with their relationship with clinical DPN markers such as hemoglobin A1c (HbA1c), age, and disease duration using multivariable linear regression. Results: The SVPTs moderately correlated with RSTF scores ( R s = −0.43, p = 0.0019). Among adults aged 50 to 69 years, SVPTs correlated significantly with clinical markers [ F (4, 29) = 4.76, p = 0.00447, Multiple R 2 = 0.396, Adjusted R 2 = 0.313, ϵ = 0.167]. The interaction between age and HbA1c was positively associated with SVPTs (β = 0.118, p = 0.001), while SVPTs were negatively associated with diabetes duration (β = −0.098, p = 0.003). Conclusions: We present a clinically relevant, patient-operated smartphone application for large-fiber sensory monitoring, tested on patients with varying DPN risk. This novel platform has the potential to provide a precise, reliable, and accessible avenue for identifying individuals at risk of developing DPN complications, prior to overt clinical manifestation.


  • Open Access

    Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report

    by Guillermo E. Umpierrez, Viral N. Shah, Veronica Brady, Mark A. Clements, Juan Espinoza, Elizabeth Healey, Michael A. Kohn, David M. Maahs, Ralph Oiknine, Jane J. Seley, et al.

    A panel of experts in the use of continuous glucose monitoring (CGM) data in the treatment of diabetes met in Burlingame, California on October 27, 2025 to discuss the utility of the glycemia risk index (GRI) for clinical care research and population health management. The GRI composite metric is a single number (on a 0-100 percentile scale—lower is better) based on an expert-determined weighting of the seven individual components in the existing ambulatory glucose profile (AGP). The GRI describes the quality of glycemia based on glucose values collected in a 14-day CGM tracing, thus providing additional insights into CGM profiles beyond the AGP. During the meeting, the mathematical derivation of the GRI metric was presented along with its use for adult and pediatric individuals with diabetes and cancer who require medications that can adversely affect the glucose concentration. Examples where the GRI provided useful insights into the quality of CGM tracings were also discussed by the expert panel. In addition, a new smartphone application, the GRI Calculator, was presented. This app calculates the GRI of a CGM tracing and provides visualization of sequential CGM tracings for a specific individual. The GRI provides a reference measurement for the accuracy of artificial intelligence (AI) models assigning levels of glycemic quality to CGM tracings intended to match the assessments of clinicians. The GRI is now part of the data visualization panel for the Integration of Connected Diabetes Device Data into the Electronic Health Record (iCoDE-2) project, which standardizes both CGM and insulin dosing data. Further exploration of the potential value of the GRI for non-insulin users needs to be undertaken. The panel unanimously recommended that CGM manufacturers and developers of data visualization software for CGMs add the GRI to their data platforms for insulin users.


  • Open Access

    Body composition changes after 6 and 12 months of dietary weight loss: insights from the DIETFITS trial

    by Sun H Kim, Ji Hye Heo, Kristen Cunanan, Christopher D Gardner

    Context: While popular weight-loss medications have raised concerns about lean mass loss, the normative effects of nonpharmacologic weight loss on body composition remain unclear. Objective: We assessed how the extent of weight loss from dietary changes affects lean mass and bone mineral content (BMC) in women and men. Methods: We conducted a secondary analysis of the DIETFITS trial (NCT01826591), a randomized controlled study with 609 adults (aged 18-50, body mass index [BMI] 28-40). Data from 323 participants (200 women, 123 men) who lost weight at 6 months and had dual-energy x-ray absorptiometry (DXA) assessments at baseline, 6 months, and 12 months were analyzed. Participants were stratified as follows: less than 5% (n = 102), 5% to 9% (n = 121), and 10% or more (n = 100). The primary outcome was the percentage of lean mass lost relative to total weight loss (%LML). Results: Baseline mean BMI (33 kg/m2) was similar across weight-loss groups and sexes. Mean percentage weight loss was greatest at 6 months (2.9%, 7.3%, 14.6% in those losing <5%, 5%-9%, and ≥10%, respectively) and was similar between sexes. %LML varied widely with weight loss of less than 5% but plateaued with greater loss. Men had higher %LML than women when weight loss was 5% or greater (median [interquartile range], 33% [24-41] vs 28% [17-36]; P < .001). All groups, except for women losing 10% or more, significantly regained weight and fat mass at 12 months, while BMC continued to decline. Conclusion: Contrary to our hypothesis, %LML plateaus with greater weight loss. Moreover, men experience greater %LML than women. The decline in BMC despite weight regain warrants further investigation.

  • Open Access

    Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy

    by Jairo A. Noreña, C. William Pike, Gavin Hui, Yasaman Motlaghzadeh, Deborah E. Sellmeyer, Joy Y. Wu, Sun H. Kim


  • Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?

    by Sun H. Kim, Gavin Hui, C. William Pike, Michael L. Jackson, Marcie Levine, Paul Kwo

    OBJECTIVE: Patients with type 2 diabetes are at an elevated risk for metabolic dysfunction–associated steatotic liver disease and advanced liver fibrosis. Multiple professional societies recommend initiating screening with a fibrosis-4 (FIB-4) index score calculation. This study aimed to evaluate the frequency of laboratory assessments necessary for FIB-4 score calculation in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A retrospective analysis of de-identified electronic medical records from 337,094 patients aged 40–75 years with type 2 diabetes was conducted to evaluate the completion rate of FIB-4 scoring and adherence to other recommended measurements and medications, including urinary albumin measurement and statin use. RESULTS: Only 33% of patients with type 2 diabetes had all necessary components for FIB-4 score calculation, although this rate increased significantly over time (odds ratio 2.51, 95% CI 2.44–2.58) in the period from 2020 to April 2024 compared with 2010–2014. Urinary albumin measurements also increased but remained low at 13% during the period from 2020 to April 2024. Prescriptions for statin and newer antihyperglycemic medications significantly increased. CONCLUSION: Our findings indicate that, although testing frequency for liver health in patients with type 2 diabetes is gradually increasing, substantial gaps in clinical practice persist.


  • Open Access

    Smartphone-based App to Assess Diabetic Peripheral Neuropathy

    by Rachel A. G. Adenekan, Adeyinka E. Adenekan, Kenneth K. Leung, Srikanth Muppidi, Sarada Sakamuri, Marilyn Tan, Sandra A. Tsai, Modupe Osikomaiya, Allison M. Okamura, Cara M. Nunez, et al.

    Background: Diabetic peripheral neuropathy (DPN) affects approximately 50% of individuals with diabetes and is a risk factor for amputations. Unfortunately, foot exams and screening tools are inconsistent and miss early-stage nerve damage. A smartphone-based application that delivers controlled vibrations, records patient responses, and computes a vibration perception thresh-old (SVPT) may present an accessible, precise monitoring avenue. This study assesses the clinical relevance and precision of SVPTs for measuring large-fiber sensory deficits in patients with diabetes. Methods: We measured SVPTs in 71 patients with pre-diabetes or diabetes and compared their efficacy with tuning fork exams. We analyzed the correlation between SVPT and Rydel-Seiffer tuning fork (RSTF) scores, along with their relationship with clinical DPN markers such as hemoglobin A1c (HbA1c), age, and disease duration using multivariable linear regression. Results: SVPTs moderately correlated with RSTF scores ( Rs = −0.43, p = 0.0019). Among adults aged 50 to 69, SVPTs correlated significantly with clinical markers ( F (4, 29) = 4.76, p = 0.00447, Multiple R 2 = 0.396, Adjusted R 2 = 0.313, ɛ = 0.167). The interaction between age and HbA1c was positively associated with SVPTs ( β = 0.118, p = 0.001), while SVPTs were negatively associated with diabetes duration ( β = −0.098, p = 0.003). Conclusions: We present a clinically relevant, patient-operated smartphone application for large-fiber sensory monitoring, tested on patients with varying DPN risk. This novel platform has the potential to provide a precise, reliable, and accessible avenue for identifying individuals at risk of developing DPN complications, prior to overt clinical manifestation.

  • The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes

    by Julia K. Mader, Jenise C. Wong, Guido Freckmann, Jose Garcia-Tirado, Irl B. Hirsch, Suzanne Bennett Johnson, David Kerr, Sun H. Kim, Rayhan Lal, Eslam Montaser, et al.

    This consensus report evaluates the potential role of continuous glucose monitoring (CGM) in screening for stage 2 type 1 diabetes (T1D). CGM offers a minimally invasive alternative to venous blood testing for detecting dysglycemia, facilitating early identification of at-risk individuals for confirmatory blood testing. A panel of experts reviewed current evidence and addressed key questions regarding CGM’s diagnostic accuracy and screening protocols. They concluded that while CGM cannot yet replace blood-based diagnostics, it holds promise as a screening tool that could lead to earlier, more effective intervention. Metrics such as time above range >140 mg/dL could indicate progression risk, and artificial intelligence (AI)-based modeling may enhance predictive capabilities. Further research is needed to establish CGM-based diagnostic criteria and refine screening strategies to improve T1D detection and intervention.


  • Optimal Population Screening Strategies for Liver Fibrosis Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease

    by W. Ray Kim, Ajitha Mannalithara, Vivek Charu, Nakia Chung, Allison Kwong, Paul Y. Kwo, Natalie J. Torok, Steven M. Asch, Sun H. Kim

    INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important public health threat, potentially leading to chronic liver disease and liver cancer. Current guidelines recommend using the Fibrosis-4 score for initial identification of subjects at risk of future complications. We formulate a novel population screening strategy based on the Steatosis-Associated Fibrosis Estimator (SAFE) score, recently developed for MASLD risk stratification in primary care. METHODS: We interrogated the National Health and Nutrition Examination Survey data, 2017–20, in which a sample of subjects representative of US civilian population underwent vibration-controlled transient elastography (VCTE). The current guideline and a new, SAFE-based proposal were applied to these data to project the number of subjects to be diagnosed with liver fibrosis gauged by liver stiffness measurement (LSM), including significant (LSM ≥8 kPa) and advanced (LSM ≥12 kPa) fibrosis, as well as the number of VCTEs to be performed. RESULTS: In the survey data, 2,691 subjects, projecting to 75.8 million US adults, were found to have MASLD, of whom 11% had LSM 8–12 kPa and 6% LSM ≥12 kPa. When the current guideline was applied, 18.1 million VCTEs would be needed to diagnose 3.5 million subjects with LSM ≥8 kPa and 1.7 million subjects with LSM ≥12 kPa. In comparison, a new approach based on the SAFE score would detect 4.9 million with LSM ≥8 kPa and 2.5 million subjects with LSM ≥12 kPa (37% and 45% improvement over the current guideline, respectively), while requiring 5.0 million fewer VCTEs (28% reduction). DISCUSSION: The proposed population risk stratification approach using the SAFE score is simpler and substantially more effective, yielding more subjects with liver fibrosis while requiring less resources compared with the currently recommended algorithm.